| P2093 | author name string | Rituparna Maiti | |
| P2860 | cites work | Metronomic chemotherapy-induced bilateral subdural hematoma in a child with meningeal carcinomatosis. | Q46012949 |
| | Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia | Q46114146 |
| | High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults | Q46408674 |
| | Secondary Ph+ acute lymphoblastic leukemia after temozolomide | Q46619232 |
| | A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer | Q46800161 |
| | Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. | Q46830983 |
| | High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. | Q53250395 |
| | CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers | Q56901953 |
| | Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer' | Q59269535 |
| | Back to the basics: the importance of concentration x time in oncology | Q70697018 |
| | Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels | Q77683633 |
| | Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study | Q80013362 |
| | Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity | Q24561642 |
| | Modes of resistance to anti-angiogenic therapy | Q24608005 |
| | Tumor angiogenesis: therapeutic implications | Q27860595 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer | Q28376841 |
| | Tumorigenesis and the angiogenic switch | Q29619849 |
| | Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer | Q33257718 |
| | Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network | Q33514751 |
| | Therapy-Induced Senescence in Cancer | Q34212773 |
| | Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice | Q34432972 |
| | The identification of senescence-specific genes during the induction of senescence in prostate cancer cells | Q34769742 |
| | Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 | Q35266125 |
| | The anti-angiogenic basis of metronomic chemotherapy | Q35788112 |
| | Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. | Q35848435 |
| | Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. | Q36952063 |
| | Immunological aspects of cancer chemotherapy | Q37039588 |
| | VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. | Q37111160 |
| | The significance of Treg cells in defective tumor immunity | Q37177121 |
| | Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells | Q37403295 |
| | Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma | Q37485279 |
| | Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package | Q38006448 |
| | A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors | Q40268444 |
| | A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy | Q43246662 |
| | Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma | Q43690341 |
| | Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. | Q44043963 |
| | Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. | Q44235692 |
| | Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide | Q45182740 |
| | Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. | Q45923784 |
| P433 | issue | 3 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 186-192 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Journal of Pharmacology & Pharmacotherapeutics | Q15816637 |
| P1476 | title | Metronomic chemotherapy | |
| P478 | volume | 5 | |